GLP-1 drugs meaningfully shrink weight and waistlines in kids with obesity, though nausea is common.
Ghassan A. Sukkar, Mumen H. Halabi and Yousef H. Faden
This meta-analysis of five randomized trials involving 600 children and adolescents with obesity found that GLP-1 receptor agonists produced meaningful reductions in BMI, body weight, waist circumference, blood sugar, and blood pressure compared to placebo. Safety was broadly comparable to placebo overall, though gastrointestinal side effects like nausea and vomiting were more common with active treatment. The authors call for larger, longer trials to confirm these benefits before widespread pediatric use.
- The question: Can the same drugs that treat adult obesity help children too?
- The study: A meta-analysis pooled five randomized trials covering 600 children and adolescents with obesity.
- The finding: Compared with placebo, GLP-1 agonists produced meaningful reductions in BMI, body weight, and waist circumference.
- The nuance: Blood sugar and blood pressure improved too, though nausea and vomiting were more common with active treatment.
Takeaway: GLP-1 agonists show real promise in pediatric obesity, but larger, longer trials are needed before routine use.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.